The competition aims to encourage new targeted cancer treatments based on the molecular signatures of cancer.
Projects must use whole genome sequencing to analyse cancer and can adopt various approaches including development of reporting tools, identification of molecular signatures, identification of therapeutic targets, and new genetic signatures.
They can focus on one or more of:
- improving diagnosis and prognosis of cancer and selection of therapies
- analysis of complex molecular signatures
- identification of tumours of unknown primary origin
- further analysis of existing whole genome sequence data held by Genomics England
- the system of sample collection provided by the genomic medicine centres
The competition will support a range of work from short feasibility studies to partners working on larger research and development projects.
- businesses of any size may apply, and all projects must include at least one SME
- we expect projects to range in size between £50,000 and £1 million
Click here to find out more.